219 related articles for article (PubMed ID: 26553741)
1. Risperidone and NAP protect cognition and normalize gene expression in a schizophrenia mouse model.
Vaisburd S; Shemer Z; Yeheskel A; Giladi E; Gozes I
Sci Rep; 2015 Nov; 5():16300. PubMed ID: 26553741
[TBL] [Abstract][Full Text] [Related]
2. New horizons in schizophrenia treatment: autophagy protection is coupled with behavioral improvements in a mouse model of schizophrenia.
Merenlender-Wagner A; Shemer Z; Touloumi O; Lagoudaki R; Giladi E; Andrieux A; Grigoriadis NC; Gozes I
Autophagy; 2014; 10(12):2324-32. PubMed ID: 25484074
[TBL] [Abstract][Full Text] [Related]
3. D-SAL and NAP: Two Peptides Sharing a SIP Domain.
Gozes I; Sragovich S; Schirer Y; Idan-Feldman A
J Mol Neurosci; 2016 Jun; 59(2):220-31. PubMed ID: 26816081
[TBL] [Abstract][Full Text] [Related]
4. ADNP/NAP dramatically increase microtubule end-binding protein-Tau interaction: a novel avenue for protection against tauopathy.
Ivashko-Pachima Y; Sayas CL; Malishkevich A; Gozes I
Mol Psychiatry; 2017 Sep; 22(9):1335-1344. PubMed ID: 28115743
[TBL] [Abstract][Full Text] [Related]
5. The cytoskeleton as a drug target for neuroprotection: the case of the autism- mutated ADNP.
Gozes I
Biol Chem; 2016 Mar; 397(3):177-84. PubMed ID: 25955282
[TBL] [Abstract][Full Text] [Related]
6. NAP (davunetide) enhances cognitive behavior in the STOP heterozygous mouse--a microtubule-deficient model of schizophrenia.
Merenlender-Wagner A; Pikman R; Giladi E; Andrieux A; Gozes I
Peptides; 2010 Jul; 31(7):1368-73. PubMed ID: 20417241
[TBL] [Abstract][Full Text] [Related]
7. The NAP motif of activity-dependent neuroprotective protein (ADNP) regulates dendritic spines through microtubule end binding proteins.
Oz S; Kapitansky O; Ivashco-Pachima Y; Malishkevich A; Giladi E; Skalka N; Rosin-Arbesfeld R; Mittelman L; Segev O; Hirsch JA; Gozes I
Mol Psychiatry; 2014 Oct; 19(10):1115-24. PubMed ID: 25178163
[TBL] [Abstract][Full Text] [Related]
8. Microtubules, schizophrenia and cognitive behavior: preclinical development of davunetide (NAP) as a peptide-drug candidate.
Gozes I
Peptides; 2011 Feb; 32(2):428-31. PubMed ID: 21050875
[TBL] [Abstract][Full Text] [Related]
9. NAP, a peptide derived from the activity-dependent neuroprotective protein, modulates macrophage function.
Quintana FJ; Zaltzman R; Fernandez-Montesinos R; Herrera JL; Gozes I; Cohen IR; Pozo D
Ann N Y Acad Sci; 2006 Jul; 1070():500-6. PubMed ID: 16888216
[TBL] [Abstract][Full Text] [Related]
10. Novel tubulin and tau neuroprotective fragments sharing structural similarities with the drug candidate NAP (Davuentide).
Gozes I; Iram T; Maryanovsky E; Arviv C; Rozenberg L; Schirer Y; Giladi E; Furman-Assaf S
J Alzheimers Dis; 2014; 40 Suppl 1():S23-36. PubMed ID: 24503616
[TBL] [Abstract][Full Text] [Related]
11. Activity-dependent neuroprotective protein (ADNP)-end-binding protein (EB) interactions regulate microtubule dynamics toward protection against tauopathy.
Ivashko-Pachima Y; Gozes I
Prog Mol Biol Transl Sci; 2021; 177():65-90. PubMed ID: 33453943
[TBL] [Abstract][Full Text] [Related]
12. NAP (davunetide) provides functional and structural neuroprotection.
Gozes I
Curr Pharm Des; 2011; 17(10):1040-4. PubMed ID: 21524250
[TBL] [Abstract][Full Text] [Related]
13. Disrupted-in-schizophrenia-1 protects synaptic plasticity in a transgenic mouse model of Alzheimer's disease as a mitophagy receptor.
Wang ZT; Lu MH; Zhang Y; Ji WL; Lei L; Wang W; Fang LP; Wang LW; Yu F; Wang J; Li ZY; Wang JR; Wang TH; Dou F; Wang QW; Wang XL; Li S; Ma QH; Xu RX
Aging Cell; 2019 Feb; 18(1):e12860. PubMed ID: 30488644
[TBL] [Abstract][Full Text] [Related]
14. Expression of DISC1 binding partners is reduced in schizophrenia and associated with DISC1 SNPs.
Lipska BK; Peters T; Hyde TM; Halim N; Horowitz C; Mitkus S; Weickert CS; Matsumoto M; Sawa A; Straub RE; Vakkalanka R; Herman MM; Weinberger DR; Kleinman JE
Hum Mol Genet; 2006 Apr; 15(8):1245-58. PubMed ID: 16510495
[TBL] [Abstract][Full Text] [Related]
15. Activity-dependent neuroprotective protein: from gene to drug candidate.
Gozes I
Pharmacol Ther; 2007 May; 114(2):146-54. PubMed ID: 17363064
[TBL] [Abstract][Full Text] [Related]
16. Protection against tauopathy by the drug candidates NAP (davunetide) and D-SAL: biochemical, cellular and behavioral aspects.
Shiryaev N; Pikman R; Giladi E; Gozes I
Curr Pharm Des; 2011; 17(25):2603-12. PubMed ID: 21728979
[TBL] [Abstract][Full Text] [Related]
17. Activity-dependent neuroprotective protein snippet NAP reduces tau hyperphosphorylation and enhances learning in a novel transgenic mouse model.
Vulih-Shultzman I; Pinhasov A; Mandel S; Grigoriadis N; Touloumi O; Pittel Z; Gozes I
J Pharmacol Exp Ther; 2007 Nov; 323(2):438-49. PubMed ID: 17720885
[TBL] [Abstract][Full Text] [Related]
18. Voluntary exercise improves cognitive deficits in female dominant-negative DISC1 transgenic mouse model of neuropsychiatric disorders.
Segal-Gavish H; Barzilay R; Rimoni O; Offen D
World J Biol Psychiatry; 2019 Mar; 20(3):243-252. PubMed ID: 28593819
[TBL] [Abstract][Full Text] [Related]
19. The autism/neuroprotection-linked ADNP/NAP regulate the excitatory glutamatergic synapse.
Sragovich S; Malishkevich A; Piontkewitz Y; Giladi E; Touloumi O; Lagoudaki R; Grigoriadis N; Gozes I
Transl Psychiatry; 2019 Jan; 9(1):2. PubMed ID: 30664622
[TBL] [Abstract][Full Text] [Related]
20. Disrupted in Schizophrenia 1 and Nudel form a neurodevelopmentally regulated protein complex: implications for schizophrenia and other major neurological disorders.
Brandon NJ; Handford EJ; Schurov I; Rain JC; Pelling M; Duran-Jimeniz B; Camargo LM; Oliver KR; Beher D; Shearman MS; Whiting PJ
Mol Cell Neurosci; 2004 Jan; 25(1):42-55. PubMed ID: 14962739
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
